Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993) shareholders have had their patience rewarded with a 26% share price jump in the last month. Looking further back, the 11% rise over the last
Ma Yinglong (600993.SH): Net profit of 198 million yuan in the first quarter increased 5.36% year over year
Gelonghui, April 19: Ma Yinglong (600993.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 955 million yuan, an increase of 14.70%; net profit attributable to shareholders of listed companies was 198 million yuan, an increase of 5.36% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 193 million yuan, an increase of 35.67% year on year; and basic earnings per share were 0.46 yuan.
Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment
Mayinglong Pharmaceutical Group (SHA:600993) has obtained a drug registration certificate from China's National Medical Products Administration to register its new colorectal treatment, according to a
Ma Yinglong (600993.SH): Compound polyethylene glycol electrolyte dispersion (III) obtained drug registration certificate
Gelonghui, April 16丨Ma Yinglong (600993.SH) announced that the company recently received the Compound Polyethylene Glycol Electrolyte Powder (III) (“the drug”) “Drug Registration Certificate” (certificate number: 2024S00546) approved and issued by the State Drug Administration. Compound polyethylene glycol electrolyte dispersion (III) is suitable for colonoscopy and removal of intestinal contents during colorectal surgery.
Estimating The Intrinsic Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)
Key Insights The projected fair value for Mayinglong Pharmaceutical Group is CN¥25.19 based on 2 Stage Free Cash Flow to Equity Mayinglong Pharmaceutical Group's CN¥25.77 share price indicates it is
Ma Yinglong (600993.SH): Net profit in 2023 fell 7.38% year on year, and plans to distribute 4 yuan for 10 shares
Gelonghui, April 12 | Ma Yinglong (600993.SH) released its 2023 annual report. Operating revenue was 3.137 billion yuan, down 11.20% year on year, net profit was 443 million yuan, down 7.38% year on year, after deducting non-net profit of 352 million yuan, down 23.61% year on year, with basic earnings of 1.03 yuan per share. A cash dividend of 4 yuan is distributed to all shareholders for every 10 shares.
Retail Investors Are Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Biggest Owners and Were Hit After Market Cap Dropped CN¥392m
Key Insights Significant control over Mayinglong Pharmaceutical Group by retail investors implies that the general public has more power to influence management and governance-related decisions The
“Emerging influencer” Ma Yinglong's sales are rising, performance is slowing down, why is transformation not working
“Investor Network” Xie Yingjie At the beginning of the new year, Ma Yinglong (600993.SH) was on the cusp of public opinion because sales of hemorrhoid cream doubled after the Spring Festival. As an old brand that was once popular in the north and south of the river, Ma Yinglong's seemingly satisfactory sales volume hides a challenge of sustainable development. On the one hand, after R&D patents expired one after another, the market share of core products declined, and market competition was fierce; on the other hand, after years of transformation, diversified industries have not developed into supporting businesses. Ma Yinglong has made many changes in recent years, including measures such as expanding channels and laying out new tracks. However, sales of new businesses have remained low so far. in
Mayinglong Pharmaceutical Group (SHSE:600993) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Mayinglong Pharmaceutical Group (SHSE:600993) Jumps 4.1% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And the truth is, you can make significant gains if you buy good
Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 5.1% Last Week
Key Insights Mayinglong Pharmaceutical Group's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 16 shareholders ow
Ma Yinglong (600993.SH): The company's sanitary wipes products are in the market expansion stage
Gelonghui November 7 | Ma Yinglong (600993.SH) said on the investor interactive platform that the company's sanitary wipes products are in the market expansion stage, and the current business volume is still small.
Ma Yinglong (600993.SH): Tofacitib citrate tablets obtained a registration certificate
Gelonghui, October 31, Ma Yinglong (600993.SH) announced that the company has received approval from the State Drug Administration for tofacitib citrate tablets “Drug Registration Certificate” (certificate number: 2023S01722). Tofacib citrate tablets are oral Janus kinase (JAK) inhibitors that selectively inhibit JAK kinase, thereby inhibiting the transformation of cellular inflammatory factors and is used to treat various inflammation-related immune diseases. Currently, domestically approved indications include rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Ma Yinglong (600993.SH) released the first three quarter results, net profit of 418 million yuan, an increase of 0.56%
Ma Yinglong (600993.SH) released the report for the third quarter of 2023, achieving revenue of 24.4 in the first three quarters...
Here's Why Mayinglong Pharmaceutical Group (SHSE:600993) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Ma Yinglong (600993.SH) released first-half results, net profit of 281 million yuan, up 3.47% year on year
Ma Yinglong (600993.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income of 1...
Declining Stock and Solid Fundamentals: Is The Market Wrong About Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)?
It is hard to get excited after looking at Mayinglong Pharmaceutical Group's (SHSE:600993) recent performance, when its stock has declined 14% over the past three months. However, stock prices are u
Ma Yinglong (600993.SH): Does not involve medium- to high-risk financial management
Glonghui, August 21: Ma Yinglong (600993.SH) said on the investor interactive platform that the company entrusts financial investment targets are mainly high-security, high-liquidity, low-risk wealth management products and monetary funds issued by financial institutions with legal operating qualifications, such as commercial banks, etc., and do not involve medium- to high-risk financial management.
Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Stock Price Dropped 3.7% Last Week; Individual Investors Would Not Be Happy
Key Insights The considerable ownership by individual investors in Mayinglong Pharmaceutical Group indicates that they collectively have a greater say in management and business strategy The top 25
Ma Yinglong (600993.SH) plans to pay $0.35 per share in 2022, excluding interest on July 28
According to the Zhitong Finance App, Ma Yinglong (600993.SH) announced that the company plans to distribute a cash dividend of 0.35 yuan (tax included) per share in 2022. The share registration date is July 27, 2023, and the delisting date is July 28, 2023.
No Data